This article was originally published in The Tan Sheet
Firm's Schiff Move Free joint supplement sales fell 2.9% in the first quarter versus the prior year period which is "unacceptable, but does indicate we are starting to stabilize the brand," CEO Bruce Wood comments in Sept. 25 earnings call. In March, Weider implemented a brand-building initiative for Move Free that included over $12 mil. in ad spending to spur its sales (1"The Tan Sheet" Aug. 18, 2003, p. 13). Wood expects low, single-digit Move Free growth in Weider's 2004 fiscal year, driven by double-digit growth at year-end. The exec also says Weider plans to launch new products "branching into new broad human condition areas, an example being cardiovascular health," in 2005...
You may also be interested in...
Weider says a recently launched brand-building initiative for its Schiff division's Move Free joint supplement product line will help return the company to positive earnings in the coming year
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.